CN1709408A - Medicine for treating anaphylactoid purpura - Google Patents
Medicine for treating anaphylactoid purpura Download PDFInfo
- Publication number
- CN1709408A CN1709408A CNA2005100505774A CN200510050577A CN1709408A CN 1709408 A CN1709408 A CN 1709408A CN A2005100505774 A CNA2005100505774 A CN A2005100505774A CN 200510050577 A CN200510050577 A CN 200510050577A CN 1709408 A CN1709408 A CN 1709408A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- rhizoma
- radix
- anaphylactoid purpura
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Chinese medicine for curing allergic purpura. Said Chinese medicine has the functions of clearing away heat, removing toxic material, removing heat from the blood and removing ecchymoses, and can obtain obvious therapeutic effect. Said Chinese medicine is made up by using 8 Chinese medicinal materials of krait/agkistrodon, ligusticum root, Chinese angelica root, dried/fresh rehmannia root, cicada molting, salvia root, moutan root bark and imperata root.
Description
Technical field:
The present invention relates to a kind of medicine for the treatment of anaphylactoid purpura, belong to the technical field of pharmaceuticals for the treatment of anaphylactoid purpura.
Background technology:
Anaphylactoid purpura is a kind of allergic disease, mainly adds up capillary wall and bleeding takes place.Show as the skin purpura clinically, the symptom of arthralgia in various degree and gastrointestinal tract, kidney aspect, lab testing can no abnormally be found.Modern medicine thinks that primary disease may act on human body by various sensitizing agent, brings out by allergy.Though it is more to treat the medicine of this disease at present, mostly is Western medicine greatly, though these Western medicine have certain curative effect, it exists the phenomenon of toxic and side effects also relatively more serious, and the patient is easy to generate the medicine dependence; And western medicine is longer the course of treatment, and lacks the method that recurs of preventing; It is higher that existing in addition Western medicine ubiquity medical expense, and the also less-than-ideal problem of curative effect, and therefore, the result of use of existing treatment allergy purpura still is not ideal.
Summary of the invention:
The objective of the invention is: provide a kind of therapeutic effect better, have no side effect, the medicine of treatment anaphylactoid purpura that medical expense is lower, to overcome the deficiencies in the prior art.
The present invention is achieved in that the medicament that this medicine is made by Agkistrodon, Rhizoma Chuanxiong, Radix Angelicae Sinensis, the Radix Rehmanniae, Periostracum Cicadae, Radix Salviae Miltiorrhizae, Cortex Moutan, Rhizoma Imperatae eight flavor Chinese medicines, and each Chinese medicine proportioning by weight of distinguishing the flavor of is: 10～20 parts of Agkistrodons, 8～15 parts of Rhizoma Chuanxiongs, 8～15 parts of Radix Angelicae Sinensis, 10～20 parts in the Radix Rehmanniae, 1～5 part of Periostracum Cicadae, 10～20 parts of Radix Salviae Miltiorrhizaes, 8～15 parts of Cortex Moutans, 10～20 parts of Rhizoma Imperataes.
The ratio range of the formula optimization weight portion of preparation medicine of the present invention is: 12～18 parts of Agkistrodons, 10～13 parts of Rhizoma Chuanxiongs, 10～13 parts of Radix Angelicae Sinensis, 12～18 parts in the Radix Rehmanniae, 2～4 parts of Periostracum Cicadaes, 12～18 parts of Radix Salviae Miltiorrhizaes, 10～13 parts of Cortex Moutans, 12～18 parts of Rhizoma Imperataes.
The proportioning of optimum weight part of medicine of the present invention is: 16 parts of Agkistrodons, 12 parts of Rhizoma Chuanxiongs, 12 parts of Radix Angelicae Sinensis, 16 parts in the Radix Rehmanniae, 3 parts of Periostracum Cicadaes, 16 parts of Radix Salviae Miltiorrhizaes, 12 parts of Cortex Moutans, 15 parts of Rhizoma Imperataes.
Agkistrodon in the above-mentioned Chinese medicine can be replaced by Zaocys.
Best medicament of the present invention is an oral liquid formulation.
In prescription of the present invention: the Agkistrodon nature and flavor are sweet, warm, return Liver Channel, have dehumidifying and dispel the wind, treat numbness antidotal effect; The Rhizoma Chuanxiong acrid in the mouth is warm in nature, goes into liver, gallbladder, pericardium channel, has the effect of calmness, analgesia, hypnosis, blood pressure lowering, coronary artery dilator, coronary blood flow increasing; Radix Angelicae Sinensis nature and flavor suffering, hardship, temperature are gone into the heart, liver, spleen channel, have enrich blood, invigorate blood circulation, menstruction regulating and pain relieving, the effect of moisturizing laxation; The sweet little bitter cold of Radix Rehmanniae nature and flavor is gone into the conscience kidney channel, has the effect of clearing away heat and cooling blood, Yin-nourishing and body fluid promoting; The Periostracum Cicadae nature and flavor are sweet, cold, go into lung, Liver Channel, have the effect of thin bone heat clearing away, lung qi dispersing rash, spasmolytic nebula removing; Radix Salviae Miltiorrhizae nature and flavor hardship is slightly cold, and goes into the conscience warp, effect such as have promoting blood circulation to remove obstruction in the collateral, blood stasis dispelling, diuretic, subside a swelling, calm the nerves; Cortex Moutan nature and flavor suffering, cold, nontoxic has the function of settling five organs, is usually used in treating diseases such as main cold and heat, apoplexy Chi Zong, infantile convulsion pathogen, carbuncle skin ulcer; Cold in nature, the sweet in the mouth of Rhizoma Imperatae has the effect of cooling blood for hemostasis, clearing away heat and promoting diuresis, is usually used in treating diseases such as heat in blood haematemesis, epistaxis, hematuria, calentura excessive thirst, jaundice, edema, the puckery pain of pyretic stranguria clinically
The present invention is according to traditional experience, and in conjunction with the pathomechanism of modern Chinese medicine, thinks that its pathogenesis of anaphylactoid purpura is the absurd row of pathogenic heat forcing blood, the QI and blood knot of fighting, and the venation of burning, so that performance appears sending out a speckle, have blood in stool etc.Therefore the present invention is directed to the characteristics of anaphylactoid purpura, through long-term experiment, comparison and research, with above-mentioned commonly used inexpensive and after the safer Chinese medicine of clinical use proof carries out rational formula, make the Chinese medicine of respectively distinguishing the flavor of to coordinate to bring into play jointly its property of medicine mutually based on heat-clearing and toxic substances removing, blood cooling and ecchymoses removing.Through clinical verification, the present invention has the effect of heat-clearing and toxic substances removing, blood cooling and ecchymoses removing preferably, and when being used for the treatment of the anaphylactoid purpura disease, compare with existing medicine, the present invention also have therapeutic effect better, short treating period, be difficult for recurring, have no side effect, advantage that medical expense is lower.
The specific embodiment:
Embodiments of the invention: get Agkistrodon 16 grams, Rhizoma Chuanxiong 12 grams, Radix Angelicae Sinensis 12 grams, the Radix Rehmanniae 16 grams, Periostracum Cicadae 3 grams, Radix Salviae Miltiorrhizae 16 grams, Cortex Moutan 12 grams, Rhizoma Imperatae 15 grams as pharmaceutical raw material, each raw material is cleaned the back to be soaked 20～30 minutes earlier with 800～1000 ml waters, decocted again 20～50 minutes after then it being boiled, medicinal residues are filtered out, get its medicinal liquid and can make oral liquid formulations of the present invention.Oral liquid formulations of the present invention also routinely the oral liquid processing technology be made; The present invention also can be made as said regular dosage form on the pharmaceutics, and as dosage forms such as tablet, pill, capsules, these dosage forms can be made by the traditional method of corresponding dosage form.
The instructions about how to take medicine of oral liquid formulations of the present invention are: every day 3 times, each 50 milliliters, general 1 month is a course of treatment.
Be the clinical observation example that employing the present invention treats patients with anaphylactoid purpura below, so that curative effect of the present invention is further described:
The patient man, 35 years old, be diagnosed as " anaphylactoid purpura " through examination in hospital, and to obey conventional antiallergic western medicine one wheat harvesting period, its purpura occurs repeatedly still, two on inspection lower limb and two upper limb ancons are seen and are dispersed in purpura before clothes the present invention, not of uniform size, that presses is colour-fast, exceeds surface, be symmetrically distributed, and ankle, wrist, joint and double knee joint pain symptom are arranged.
Check after ten days through taking the present invention, its lower limb purpura is faded out, and ankle, wrist, arthralgia alleviate, but double knee joint pain still.
Continue to take the present invention's check again after 15 days again, its pair lower limb and two upper limb ancon purpura complete obiteration, its ankle, wrist, joint and the also complete obiteration of double knee joint pain.
Phone is paid a return visit the patient after 1 year, does not see recurrence.
Taking during the present invention treats, any untoward reaction does not appear in the patient.
Claims (5)
1, a kind of medicine for the treatment of anaphylactoid purpura, it is characterized in that: the medicament that this medicine is made by Agkistrodon, Rhizoma Chuanxiong, Radix Angelicae Sinensis, the Radix Rehmanniae, Periostracum Cicadae, Radix Salviae Miltiorrhizae, Cortex Moutan, Rhizoma Imperatae eight flavor Chinese medicines, each Chinese medicine proportioning by weight of distinguishing the flavor of is: 10～20 parts of Agkistrodons, 8～15 parts of Rhizoma Chuanxiongs, 8～15 parts of Radix Angelicae Sinensis, 10～20 parts in the Radix Rehmanniae, 1～5 part of Periostracum Cicadae, 10～20 parts of Radix Salviae Miltiorrhizaes, 8～15 parts of Cortex Moutans, 10～20 parts of Rhizoma Imperataes.
2, the medicine of treatment anaphylactoid purpura according to claim 1 is characterized in that: each Chinese medicine optimum ratio scope by weight of distinguishing the flavor of is: 12～18 parts of Agkistrodons, 10～13 parts of Rhizoma Chuanxiongs, 10～13 parts of Radix Angelicae Sinensis, 12～18 parts in the Radix Rehmanniae, 2～4 parts of Periostracum Cicadaes, 12～18 parts of Radix Salviae Miltiorrhizaes, 10～13 parts of Cortex Moutans, 12～18 parts of Rhizoma Imperataes.
3, the medicine of treatment anaphylactoid purpura according to claim 1 is characterized in that: each Chinese medicine best proportioning by weight of distinguishing the flavor of is: 16 parts of Agkistrodons, 12 parts of Rhizoma Chuanxiongs, 12 parts of Radix Angelicae Sinensis, 16 parts in the Radix Rehmanniae, 3 parts of Periostracum Cicadaes, 16 parts of Radix Salviae Miltiorrhizaes, 12 parts of Cortex Moutans, 15 parts of Rhizoma Imperataes.
4, according to the medicine of claim 1,2 or 3 described treatment anaphylactoid purpura, it is characterized in that: Agkistrodon can be replaced by Zaocys.
5, the medicine of treatment anaphylactoid purpura according to claim 1 is characterized in that: said medicament is an oral liquid formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100505774A CN1284593C (en) | 2005-07-05 | 2005-07-05 | Medicine for treating anaphylactoid purpura |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100505774A CN1284593C (en) | 2005-07-05 | 2005-07-05 | Medicine for treating anaphylactoid purpura |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1709408A true CN1709408A (en) | 2005-12-21 |
| CN1284593C CN1284593C (en) | 2006-11-15 |
Family
ID=35705740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100505774A Expired - Fee Related CN1284593C (en) | 2005-07-05 | 2005-07-05 | Medicine for treating anaphylactoid purpura |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1284593C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810835A (en) * | 2010-05-26 | 2010-08-25 | 泰一和浦（北京）中医药研究院有限公司 | Chinese medicinal composition for treating purpura and preparation method thereof |
| CN103071068A (en) * | 2013-01-22 | 2013-05-01 | 李承平 | Cicada wind-dispelling and cooling tablet |
| CN104688917A (en) * | 2015-03-28 | 2015-06-10 | 淄博夸克医药技术有限公司 | Traditional Chinese medicine for curing anaphylactoid purpura |
-
2005
- 2005-07-05 CN CNB2005100505774A patent/CN1284593C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810835A (en) * | 2010-05-26 | 2010-08-25 | 泰一和浦（北京）中医药研究院有限公司 | Chinese medicinal composition for treating purpura and preparation method thereof |
| CN103071068A (en) * | 2013-01-22 | 2013-05-01 | 李承平 | Cicada wind-dispelling and cooling tablet |
| CN104688917A (en) * | 2015-03-28 | 2015-06-10 | 淄博夸克医药技术有限公司 | Traditional Chinese medicine for curing anaphylactoid purpura |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1284593C (en) | 2006-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1839941A (en) | Chinese prepared medicine for treating bone pain | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN101095761A (en) | Chinese traditional medicine for treating appendicitis and method for preparing the same | |
| CN104758487A (en) | Traditional Chinese medicine composition for treating exfoliative cheilitis | |
| CN112972635B (en) | A Chinese medicinal composition for treating chronic kidney diseases and chronic renal failure | |
| CN103239579B (en) | Chinese medicine composition for treating acute facioplegia and preparation method thereof | |
| CN1284593C (en) | Medicine for treating anaphylactoid purpura | |
| CN100386106C (en) | Medicine for treating acne and its preparation | |
| CN104689132A (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN103977367A (en) | Traditional Chinese medicament for treating qi-stagnation blood-aggregation type bedsore and preparation method thereof | |
| CN100579544C (en) | Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof | |
| CN102940693A (en) | Medicine composition for treating diabetic foot | |
| CN102940757A (en) | Medicine composition for treating diabetic foot | |
| CN103479763B (en) | Traditional Chinese medicine composition for treating borderline hypertension and preparation method thereof | |
| CN102406893A (en) | Chinese patent medicine for treating psoriasis. | |
| CN102552520A (en) | Blood circulation-promoting and pain-stopping medicament for treating chest stuffiness and pains and preparation process and application thereof | |
| CN1312085A (en) | Dermatosis treating medicine | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN105327244A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and used for treating bedsores and preparing method thereof | |
| CN104800772A (en) | Traditional Chinese medicine composition for treating vital-energy-depression type coronary heart disease and application of traditional Chinese medicine composition | |
| CN100444871C (en) | Atoxic traditional Chinese medicine composition for treating rheumatosis and rheumatoid disease | |
| CN100398143C (en) | Medicament for treating vitiligo | |
| CN1709400A (en) | Medicine for treating ulcer haemorrhage | |
| CN102552824B (en) | Traditional Chinese medicine prepared prescription for treating psoriasis | |
| CN102423458A (en) | Chinese patent medicine for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |